Meta-Analysis of Clinical Efficacy and Bleeding Risk With Intravenous Glycoprotein IIb/IIIa Antagonists for Percutaneous Coronary Intervention

Canadian Journal of Cardiology - Canada
doi 10.1016/s0828-282x(07)70858-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention Treated With the Glycoprotein IIb/IIIa Inhibitor Tirofiban

Military Medical Research
Medicine
2016English

Glycoprotein IIb/IIIa Induced Coronary Thrombolysis

Heart
2002English

A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis of Contemporary Randomized Controlled Trials

Circulation: Cardiovascular Interventions
Cardiovascular MedicineCardiology
2009English

Lesions and Identification of Crystalline Precipitates of Glycoprotein IIb-IIIa Antagonists in the Rat Kidney

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
1999English

Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

JAMA - Journal of the American Medical Association
Medicine
2000English

Preparation and Pharmacological Evaluation of Novel Glycoprotein (Gp) IIb/IIIa Antagonists. 2. Condensed Heterocyclic Derivatives.

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
1999English

Deaths Associated With Platelet Glycoprotein IIb/IIIa Inhibitor Treatment

Heart
2003English

Platelet Inhibition With an Antibody to Glycoprotein IIb/IIIa

Circulation
Cardiovascular MedicinePhysiologyCardiology
1989English

Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin During Percutaneous Coronary Intervention: Systematic Review and Meta-Analysis

BMJ
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy